Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgical Endoscopy
Published in: Surgical Endoscopy 1/2011

01-01-2011 | Letter

Standards, advances and challenges in laparoscopic total mesorectal excision

Authors: Dimitrios H. Roukos, Christos Katsios

Published in: Surgical Endoscopy | Issue 1/2011

Login to get access

Excerpt

Total mesorectal excision (TME) has been an integral and crucial part of surgical treatment of rectal cancer. This surgical procedure, together with appropriate adjuvant treatment strategy, can improve outcomes of patients with rectal cancer. For the vast majority of patients, a sphincter-preserving treatment strategy is of fundamental importance. As a result of intensive research endeavour, low anterior resection (LAR) has been developed, and many patients benefit from this surgical approach. However, in many cases, decision-making between LAR and total rectal excision is currently too difficult, as criteria for surgical decisions have not been standardized and there is debate among surgeons about the optimal surgery for patients with low-lying rectal cancer. …
Literature
1.
Poon JT, Law WL (2009) Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol 16(11):3038–3047CrossRefPubMed
2.
Peeters KC (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246(5):693CrossRefPubMed
3.
Peeters KC, Tollenaar RA, Marijnen CA, Klein Kranenbarg E, Steup WH, Wiggers T, Rutten HJ, van de Velde CJ, Dutch Colorectal Cancer Group (2005) Risk factors for anastomotic failure after total mesorectal excision of rectal cancer. Br J Surg 92(2):211–216CrossRefPubMed
4.
Matthiessen P, Hallböök O, Rutegård J, Simert G, Sjödahl R (2007) Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg 246(2):207–214CrossRefPubMed
5.
Cheung YM, Lange MM, Buunen M, Lange JF (2009) Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc 23:2796–2801CrossRef
6.
Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27(35):5924–5930CrossRefPubMed
7.
Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27(35):5931–5937CrossRefPubMed
8.
Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF (2009) Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 96(10):1196–1204CrossRefPubMed
9.
Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS (2009) The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. Oncology 77(3–4):224–230CrossRefPubMed
10.
Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19):1308–1324 ReviewCrossRefPubMed
11.
Choi GS, Park IJ, Kang BM, Lim KH, Jun SH (2009) A novel approach of robotic-assisted anterior resection with transanal or transvaginal retrieval of the specimen for colorectal cancer. Surg Endosc 23:2831–2835CrossRef
12.
Luca F, Cenciarelli S, Valvo M, Pozzi S, Faso FL, Ravizza D, Zampino G, Sonzogni A, Biffi R (2009) Full robotic left colon and rectal cancer resection: technique and early outcome. Ann Surg Oncol 16(5):1274–1278CrossRefPubMed
13.
Hellan M, Anderson C, Ellenhorn JD, Paz B, Pigazzi A (2007) Short-term outcomes after robotic-assisted total mesorectal excision fro rectal cancer. Ann Surg Oncol 14:3168–3173CrossRefPubMed
Metadata
Title
Standards, advances and challenges in laparoscopic total mesorectal excision
Authors
Dimitrios H. Roukos
Christos Katsios
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Surgical Endoscopy / Issue 1/2011
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-010-1064-4

Other articles of this Issue 1/2011

Surgical Endoscopy 1/2011 Go to the issue

OriginalPaper

Hybrid natural orifice transluminal endoscopic cholecystectomy: prospective human series

OriginalPaper

Robotic-assisted laparoscopic surgery for recurrent diverticulitis: experience in consecutive cases and a review of the literature

OriginalPaper

Treatment strategy for recurrent or residual colorectal tumors after endoscopic resection

OriginalPaper

Comparison of laparoscopic and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases

OriginalPaper

S052: a comparison of robot-assisted, laparoscopic, and open surgery in the treatment of rectal cancer

Letter

Can mathematic formulas help us with our patients?